Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorazepam vs Midazolam for Pediatric Sedation
NCT00109395Phase 3Completed
- Sponsor
- Emmes
- Start
- Sep 2004
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of lorazepam in critical illness (3 arms), sponsored by Emmes. Primary endpoints: Rate of Severe Adverse Events, Number of bolus doses required to achieve a comfort score of 17 ≤ 26 and 1 more. Started Sep 2004; status: completed.
02
Drugs
lorazepam
03
Conditions
critical illness
Beyond the preview
Go deeper on NCT00109395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00109395.